Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.

J Addict Med · 2019 · PMC6844648 · PMID 30844878

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.0630

boldest claim

The sentences

borderline significanceP = 0.053so close (0.05 < p ≤ 0.1)

The difference in EQ-5D-5L index least squares (LS) mean change from baseline at week 25 for BUP-XR versus placebo was statistically significant for BUP-XR 300/300 mg ( P = 0.003) and had borderline significance for 300/100 mg ( P = 0.053) compared with placebo (Table 2 ).

also in 7,017 other papers

did not reach statistical significanceP = 0.063so close (0.05 < p ≤ 0.1)

The difference in SF-36v2 MCS LS mean change from baseline at week 25 were numerically improved but did not reach statistical significance for either BUP-XR 300/300 mg ( P = 0.063) or 300/100 mg ( P = 0.097) compared with placebo.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.